| Literature DB >> 35241965 |
Farah Shahid1, Youssef Saeed Alghamdi2, Mutaib Mashraqi3, Mohsin Khurshid4, Usman Ali Ashfaq1.
Abstract
Shigella sonnei is one of the major causes of diarrhea and remained a critical microbe responsible for higher morbidity and mortality rates resulting from dysentery every year across the world. Antibiotic therapy of Shigella diseases plays a critical role in decreasing the prevalence as well as the fatality rate of this infection. However, the management of these diseases remains challenging, owing to the overall increase in resistance against many antimicrobials. The situation necessitates the rapid development of effective and feasible S. sonnei treatments. In the present study, the subtractive genomics approach was utilized to find the potential drug targets for S. sonnei strain Ss046. Various tools of bioinformatics were implemented to remove the human-specific homologous and pathogen-specific paralogous sequences from the bacterial proteome. Then, metabolic pathway and subcellular location analysis were performed of essential bacterial proteins to describe their role in various cellular processes. Only one essential protein i-e Chromosomal replication initiator protein DnaA was found in the proteome of the pathogen that could be used as a potent target for designing new drugs. 3D structure prediction of DnaA protein was carried out using Phyre 2. Molecular docking of 5000 phytochemicals was performed against DnaA to identify four top-ranked phytochemicals (Riccionidin A, Dothistromin, Fustin, and Morin) based on scoring functions and interaction with the active site. This study suggests that these phytochemicals could be used as antibacterial drugs to treat S. sonnei infections in the future. To confirm their efficacy and evaluate their drug potency, further in vitro analyses are required.Entities:
Keywords: Bioinformatics; Chromosomal replication initiator protein DnaA; Drug target; Molecular docking; Phytochemicals; Shigella sonnei
Year: 2021 PMID: 35241965 PMCID: PMC8886675 DOI: 10.1016/j.sjbs.2021.09.051
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.219
Fig. 1A schematic representation of the identification of novel drug targets in Shigella sonnei.
Fig. 2Summary of subtractive genomics approach employed in this study from core proteome retrieval to essential drug target prediction.
Fig. 3Frequency Distribution of proteins involved in unique metabolic pathways of Shigella sonnei (Strain Ss046).
Fig. 4Classification of seven identified unique metabolic pathways according to biochemical processes.
Unique metabolic pathways of essential nonhomologous proteins.
| Protein Name (ID) | Pathway ID | Common Pathway | Unique Pathway |
|---|---|---|---|
| 3-methyl-2-oxobutanoate hydroxymethyltransferase (Q3Z5M6) | ssn00770 | Pantothenate and CoA biosynthesis | Biosynthesis of secondary metabolites |
| Glutamate-1-semialdehyde 2,1-aminomutase (Q3Z5K3) | ssn00860 | Porphyrin and chlorophyll metabolism | Biosynthesis of secondary metabolites |
| Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha (Q3Z5H3) | ssn01100 | Metabolic pathways | Biosynthesis of secondary metabolites |
| 1-deoxy-D-xylulose-5-phosphate synthase (Q3Z4Y9) | ssn01100 | Metabolic pathways | Microbial metabolism in diverse environments |
| Ferrochelatase (Q3Z4S4) | ssn00860 | Porphyrin and chlorophyll metabolism | Biosynthesis of secondary metabolites |
| Phosphate acyltransferase (Q3Z327) | ssn00561 | Glycerolipid metabolism | Biosynthesis of secondary metabolites |
| Enoyl-[acyl-carrier-protein] reductase [NADH] (Q3Z136) | ssn00061 | Fatty acid biosynthesis | Biosynthesis of secondary metabolites |
| Glutamyl-tRNA reductase (Q3Z0S8) | ssn00860 | Porphyrin and chlorophyll metabolism | Biosynthesis of secondary metabolites |
| Glutamate--tRNA ligase (Q3YZD6) | ssn00860 | Porphyrin and chlorophyll metabolism | Biosynthesis of secondary metabolites |
| 4-hydroxy-tetrahydrodipicolinate synthase (Q3YZ74) | ssn01230 | Biosynthesis of amino acids | Monobactam biosynthesis |
| Succinyl-diaminopimelate desuccinylase (Q3YZ81) | ssn01230 | Biosynthesis of amino acids | Microbial metabolism in diverse environments |
| Transketolase (Q3YZ88) | ssn01200 | Carbon metabolism | |
| Chromosomal replication initiator protein DnaA (Q3YWB2) | ssn02020 | Two-component system | |
| Membrane protein insertase YidC (Q3YWA8) | ssn02024 | Protein export | Quorum sensing |
| Glycerol-3-phosphate dehydrogenase [NAD(P) + ] (Q3YVX3) | ssn00564 | Glycerophospholipid metabolism | Biosynthesis of secondary metabolites |
| Glutamine synthetase (Q3YVA3) | ssn01230 | Biosynthesis of amino acids | Two-component system |
Fig. 6Strctural Analysis of DnaA Protein: (A) the DnaA protein contains α-helix (50.32%, 235), β-strand (9.64%, 45) and random coil (40.04%, 187); (B) the Ramachandran plot of the refined structure shows 98.1%, 1.9% and 0.0% residues in favored, allowed and disallowed region, respectively; (C) the z-score (-8.04) of the DnaA protein.
Fig. 5The three-dimensional structure of the Chromosomal replication initiator protein. Orange color represents alpha helixes, purple color represents beta sheets, and grey color represents loops.
Fig. 7Topology of DnaA protein predicted by OPM-PPM server.
Interaction detail of top four bioactive phytochemicals in the proposed site of DnaA protein.
| Sr no | PubChem Id | Chemical name | Docking score | Interaction detail | |
|---|---|---|---|---|---|
| rmsd value | Residues | ||||
| 1 | 441,775 | Riccionidin A | −17.6 | 0.8 | Glu 335 |
| 2 | 108,014 | Dothistromin | −16.9 | 1.3 | Ser 331 |
| 3 | 5,317,435 | Fustin | −16.6 | 1.5 | Ser 331 |
| 4 | 5,281,670 | Morin | −16.4 | 1.3 | Glu 335 |
Fig. 8A: Docked Riccionidin in complex with DnaA; side chains atoms of Glu 335 and Thr 174 making hydrogen bonds, shown in the green line. The docked pose of the compound visualized by Chimera is shown at right. B: Docked Dothistromin in complex with DnaA; side chains atoms of Ser 331, Arg 432, and Asp 427 making hydrogen bonds, shown in the green line. The docked pose of the compound visualized by Chimera is shown at right. C: Docked Fustin in complex with DnaA; side chains atoms of Ser 331 and Arg 432 making hydrogen bonds, shown in the green line. The docked pose of the compound visualized by Chimera is shown at right. D: Docked Morin in complex with DnaA; side chains atoms of Glu 335, Ser 331, Arg 432, and Asp 427 making hydrogen bonds, shown in the green line. The docked pose of the compound visualized by Chimera is shown at right.
Results of compounds examined for Lipinski rule.
| Compound | Molecular weight (g/mol) | Number of HBA | Number of HBD | MLogP |
|---|---|---|---|---|
| Lipinski rule of five | <500 | <10 | <5 | <5 |
| Riccionidin A | 285.23 | 6 | 4 | −0.67 |
| Dothistromin | 372.29 | 9 | 5 | 1.49 |
| Fustin | 288.25 | 6 | 4 | 0.80 |
| Morin | 302.24 | 6 | 5 | 1.88 |
ADMET Profiling Enlisting Absorption, Metabolism and Toxicity related drug-like parameters of candidate compounds.
| A. ADMET Profiling | ||||
|---|---|---|---|---|
| Compounds | Riccionidin A | Dothistromin | Fustin | Morin |
| A. Absorption | ||||
| Blood-Brain Barrier | + | _ | _ | _ |
| Human Intestinal Absorption | + | + | + | + |
| P-glycoprotein substrate | _ | _ | _ | _ |
| CYP450 1A2 Inhibitor | Yes | No | Yes | Yes |
| CYP450 2C9 Inhibitor | No | No | Yes | Yes |
| CYP450 2D6 Inhibitor | No | No | No | No |
| CYP450 2C19 Inhibitor | No | No | No | Yes |
| CYP450 3A4 Inhibitor | No | No | No | Yes |
| Distribution | ||||
| Subcellular localization | Mitochondria | Mitochondria | Mitochondria | Mitochondria |
| Toxicity | ||||
| AMES Toxicity | No | No | No | No |
Prediction of oral acute toxicity, class and accuracy, organ toxicity and genetic toxicity endpoints of candidate compounds (IA: Inactive).
| Sr. | Compounds Name | Oral LD50 Value (mg/kg) | Predicted Toxicity Class | Prediction Accuracy (%) | Hepatotoxicity | Probability | Cytotoxicity | Probability |
|---|---|---|---|---|---|---|---|---|
| 1 | Riccionidin A | 2991 | IV | 67.38% | IA | 0.77 | IA | 0.89 |
| 2 | Dothistromin | 3000 | V | 68.07% | IA | 0.75 | IA | 0.76 |
| 3 | Fustin | 2000 | IV | 72.9% | IA | 0.7 | IA | 0.98 |
| 4 | Morin | 3919 | V | 69.26% | IA | 0.68 | IA | 0.98 |
Fig. 9Graphical representation of predicted dose value distribution for candidate compounds (A = Riccionidin A; B = Dothistromin; C = Fustin; D = Morin;).
Prediction of genetic toxicity endpoints of candidate compounds (IA: Inactive).
| Sr. No | Compounds name | Cytotoxicity | Probability | Mutagenicity | Probability |
|---|---|---|---|---|---|
| 1 | Riccionidin A | IA | 0.89 | IA | 0.55 |
| 2 | Dothistromin | IA | 0.76 | IA | 0.56 |
| 3 | Fustin | IA | 0.98 | IA | 0.53 |
| 4 | Morin | IA | 0.98 | IA | 0.52 |